Drug Profile


Alternative Names: YKP3089

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator SK biopharmaceuticals
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Anxiolytics; Azoles; Carbamates; Mood stabilisers; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Partial epilepsies
  • Phase II Bipolar disorders; Neuropathic pain
  • Discontinued Anxiety disorders

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Sep 2015 Discontinued - Phase-I for Anxiety disorders (In volunteers) in USA (PO)
  • 21 Aug 2015 SK Life Science plans a phase III trial for Partial epilepsies (Adjunctive treatment) in USA (NCT02535091)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top